Windlas Biotech Limited , a leading player in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry, is actively pursuing stronger export growth and margin expansion through a series of strategic initiatives.

Leveraging FDA-Compliant Facilities for Export Growth

The company is capitalizing on its U.S. FDA-compliant facilities to drive export growth. This move is expected to open up new opportunities in the highly regulated U.S. market, potentially leading to increased revenue from international operations.

Expanding CDMO Partnerships

Windlas Biotech is forming new partnerships in the Contract Development and Manufacturing Organization (CDMO) segment. These collaborations are likely to enhance the company's capabilities and expand its client base, contributing to overall growth.

Diversifying Product Portfolio

The company is expanding its capabilities across various areas:

1. Nutrition
2. Injectable products
3. Contract manufacturing

This diversification strategy aims to broaden Windlas Biotech's product offerings and tap into new market segments.

Focus on Margin Expansion

Windlas Biotech is implementing two key strategies to improve its profit margins:

1. High-value product mix: By focusing on more complex and specialized products, the company aims to increase its average revenue per unit.
2. Integration with global pharmaceutical supply chains: This move is expected to optimize costs and improve operational efficiency.

Financial Performance

The company's strategic initiatives appear to be yielding positive results, as evidenced by its recent financial performance:

The company has reported its 11th consecutive quarter of record revenue, with a strong performance across all three business verticals: Generic Formulations CDMO, Trade Generics and Institutional, and Exports.

Vertical Performance

1. Generic Formulations CDMO:

   • H1 FY26 revenue: ₹3,206 crore (up 17.8% YoY)
   • Contributed 74% to consolidated revenue

2. Trade Generics & Institutional:

   • H1 FY26 revenue: ₹960 crore (up 24.7% YoY)
   • Contributed 22% to consolidated revenue

3. Exports:

   • H1 FY26 revenue: ₹159 crore (up 23.4% YoY)
   • Contributed 4% to consolidated revenue

Infrastructure Investments

Windlas Biotech continues to strengthen its manufacturing infrastructure:

• The Plant-2 extension, operational since Q4 FY25, is now contributing significantly to the business.
• The company's Injectables facility has gained further customer approvals, with commercial supplies ramping up across both CDMO and Trade Generics verticals.
• Plant 6 expansion is progressing well and is on track for commissioning within FY26.

Management Commentary

Hitesh Windlass, Managing Director of Windlas Biotech, commented on the results: "Despite the subdued industry volume growth, we are pleased to report another strong quarter, delivering a revenue increase of 19% in both Q2 FY26 and H1 FY26. The growth was driven by steady and balanced contributions across all three business verticals—Generic Formulations CDMO, Trade Generics and Institutional, and Exports—with quality standards remaining at the core of our strategy."

Komal Gupta, CEO & CFO, added: "As we move ahead, our focus remains on strengthening core capabilities and enhancing efficiencies. With disciplined execution and strong customer partnerships, Windlas Biotech is well-positioned to capture opportunities and deliver sustained value for all stakeholders."

The company's strategic focus on export growth, margin expansion, and diversification, coupled with its strong financial performance, positions Windlas Biotech for continued growth in the pharmaceutical CDMO sector.

Windlas Biotech Limited , a leading player in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry, has reported a robust financial performance for the second quarter of fiscal year 2026.

Financial Highlights

The company's unaudited consolidated financial results for Q2 FY26 show significant growth across key metrics:

Half-Yearly Performance

For the first half of FY26, Windlas Biotech achieved its highest-ever revenue:

Dividend Declaration

The Board of Directors has approved a final dividend of Rs 5.80 per share for FY 2024-25, resulting in a total dividend payout of Rs 121.56 crore.

Operational Highlights

• Generic Formulations CDMO vertical, the company's largest business segment, grew by 17.7% YoY in Q2 FY26.
• Trade Generics & Institutional vertical showed strong growth of 24.2% YoY in Q2 FY26.
• Exports vertical expanded by 13.0% YoY in Q2 FY26.

Management Commentary

Mr. Hitesh Windlass, Managing Director of Windlas Biotech, stated, "Despite subdued industry volume growth, we are pleased to report another strong quarter, delivering a revenue increase of 19% in both Q2 FY26 and H1 FY26. The growth was driven by steady and balanced contributions across all three business verticals."

Ms. Komal Gupta, CEO & CFO, added, "Windlas Biotech continued its growth trajectory, delivering the 11th consecutive quarter of record revenue performance. In Q2 FY26, EBITDA stood at Rs 286 crore and PAT at Rs 178 crore, while gross margin improved by 68 basis points YoY."

Future Outlook

The company continues to strengthen its manufacturing infrastructure through sustained investments in capacity enhancement. The Plant-2 extension is now contributing meaningfully to the business, and the Injectables facility has gained further customer approvals. Plant 6 expansion is advancing well and is on track to be commissioned within FY26.

Windlas Biotech remains focused on enhancing operational efficiency, talent empowerment, sustained investment in quality and compliance, and capability expansion across dosage forms to drive long-term shareholder value.

The company's strong performance, coupled with its strategic initiatives and focus on sustainable growth, positions it well to capture future opportunities in the pharmaceutical CDMO space.